Neurochase is the leading global biotechnology company focused exclusively on innovative devices and consulting services for CNS drug delivery. ​
​
Founded in 2020 by Professor Steven Gill, Neurochase is dedicated to commercializing safe and effective solutions to deliver targeted treatments for the most devastating neurological disorders currently impacting hundreds of millions of patients of all ages around the globe. ​
​
During the last five years, Professor Gill and his highly skilled team have developed the world’s first fast, accurate, and scalable Convection Enhanced Delivery (CED) platform for gene therapy, as well as a novel platform for cell therapy, both designed to bypass the blood-brain barrier. These platforms aim to address the unmet needs of pharmaceutical partners working on therapies that require a direct infusion to structures deep within the brain, whether they are acute or chronic in nature. ​
​
We firmly believe our pioneering systems will have a transformative impact and deliver a better way to treat life-limiting and life-threatening diseases, including, but not limited to: MND/ALS, Parkinson’s Disease, Alzheimer’s Disease, Huntington’s Disease, Epilepsy, DIPG, Glioblastoma, and other rare neurological diseases.